Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions

Area of Science:

• Neuroscience
• Translational Medicine
• Pharmacology

Background:

• Neuroprotective drug development for acute stroke has a history of failure in human trials despite promising animal model results.
• Key challenges include differences in outcome measures, study duration, ischemia models, and drug administration timing between preclinical and clinical research.
• Previous clinical trials were limited by factors such as long time windows, inadequate statistical power, insensitive outcome measures, and failure to target specific stroke subtypes or the ischemic penumbra.

Purpose of the Study:

• To review critical challenges in translational stroke research, focusing on the disconnect between animal models and human clinical trials.
• To explore new concepts in ischemic pathophysiology to inform the design of future therapeutic strategies.
• To advance the development of novel therapies for acute and subacute stroke by addressing limitations in current research and clinical trial designs.

Main Methods:

• Comparative analysis of neuroprotection assessment in preclinical stroke studies versus clinical trials.
• Review of limitations in traditional clinical trial designs, including time windows, statistical power, outcome measures, and patient selection.
• Exploration of emerging concepts in ischemic pathophysiology, including multiagent therapy and neuroplasticity.

Main Results:

• Preclinical studies often rely on infarct volume, short-term outcomes, transient ischemia, and short drug windows, differing from clinical trial realities.
• Clinical trials have been hampered by long administration windows, insufficient power, insensitive measures, protocol violators, and lack of targeted approaches.
• A significant disconnect exists in how neuroprotection is evaluated, impacting the translation of preclinical findings to clinical efficacy.

Conclusions:

• Recognizing the limitations of animal models and past clinical trials is essential for improving translational stroke research.
• Future research should consider extended time windows, functional outcomes, permanent ischemia models, and targeting both gray and white matter.
• Exploring multiagent therapies and leveraging brain plasticity offers promising avenues for developing effective treatments for acute and subacute stroke.